We recently looked at the top pharmaceutical companies across developed markets to assess how successful they’ve been in reducing their natural capital impacts.
Our analysis found that only 3 of the largest companies (by revenue) in developed markets outperformed the sector average in terms of reducing their overall natural capital impacts (measured by impact intensities as seen in the graph below). AstraZeneca performed the best in reducing their overall natural capital impacts, reducing it by 19%, with Amgen and Zoetis also reducing their impacts by 14% and 12% respectively.
Zooming in to just GHG emissions, the picture looks better: the top 10 companies in developed markets performed well in reducing their GHG emissions compared to the industry average ($570 per million USD revenue). Vertex Pharmaceuticals and AstraZeneca led the way with 28% and 20% impact reduction rates respectively, outpacing the average GHG impact reduction rate of 12%.
Finally we noticed how Zoetis and AstraZeneca stood out in reducing their waste impact intensity compared to the sector average, reducing their waste intensity by 20% and 19% respectively. Meanwhile, some of their peers, like AbbVie saw a concerning 64% increase in waste impact intensity over the same period.
If you’re interested in evaluating your company’s environmental impact across its operations and comparing it with industry peers, get in touch with GIST Impact. Our platform can assist you in measuring and benchmarking your environmental performance within the sector, giving you location-specific, cross-comparable insights so you can fully understand what’s most material to your business.
Learn more about our solution on Environmental Benchmarking or reach out to us at info@gistimpact.com.
The MSCI ACWI is one of the world’s most well-known indices, serving as the benchmark for ca. USD 5 trillion in assets under management. The MSCI ACWI is the world…
We’re proud to share that GIST Impact has won the FStech Award for ‘𝗘𝗦𝗚 𝗮𝗻𝗱 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿’! With huge thanks to our incredible team for their dedication…
At GIST Impact, we’re excited to introduce our Climate, Nature, and Biodiversity Portfolio Analysis Tool—a science-backed, location-specific solution designed to bring clarity and actionability to nature-related finance. ✅ Delivering actionable,…
Compliance is complicated. But it really doesn’t have to be. The Corporate Sustainability Reporting Directive (CSRD) is reshaping how businesses disclose their sustainability impacts—but navigating its complexities can be incredibly…
The EU Omnibus package has arrived, and while the dust is yet to settle, it’s still a significant milestone on the road to impact-driven regulation. Yes, there have been eye-watering…
The UK Social Value Model has undergone significant changes, reflecting a growing emphasis on social sustainability and community impact. These changes are not just bureaucratic adjustments; they represent a fundamental…